Development of hepatitis C virus vaccines: challenges and progress.
Abstract
Development of an effective vaccine against the hepatitis C virus (HCV) has long been defined as a difficult challenge due to the considerable variability of this RNA virus and the observation that convalescent humans and chimpanzees could be re-infected after re-exposure. On the other hand, progress in the understanding of antiviral immune responses in patients with viral clearance has elucidated key mechanisms playing a role in the control of viral infection. Studies investigating prophylactic vaccine approaches in chimpanzees have confirmed that the induction and maintenance of strong helper and cytotoxic T-cell immune responses against multiple viral epitopes is necessary for protection against viral clearance and chronic infection. A multispecific B-cell response, resulting in rapid induction of cross-neutralizing antibodies may assist cellular responses. Therapeutic vaccine formulations currently being evaluated in clinical trials are facing the fact that the immune system of chronic carriers is impaired and needs the restoration of T-cell functions to enhance their efficacy.
Domains
Hépatology and Gastroenterology
Fichier principal
Stoll-Keller_vaccine_review_FINAL.pdf (242.84 Ko)
Télécharger le fichier
inserm-00517322_edited.pdf (285.11 Ko)
Télécharger le fichier
Vaccine_Figure_1.pdf (196.63 Ko)
Télécharger le fichier
Vaccine_Table_1_FINAL.pdf (61.66 Ko)
Télécharger le fichier
Vaccine_Table_2_FINAL.pdf (70.06 Ko)
Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Loading...